comparemela.com
Home
Live Updates
Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) : comparemela.com
Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug...
Related Keywords
United Kingdom ,
Houston ,
Texas ,
United States ,
Poland ,
British ,
Polish ,
Jenene Thomas ,
Walter Klemp ,
John Paul Waymack Moleculin ,
Liposomal Annamycin ,
Priebe Moleculin ,
Wolfram Dempke Moleculin ,
Exchange Commission ,
Drug Administration ,
Securities Exchange ,
Linkedin ,
British Journal Of Cancer Research ,
Facebook ,
Moleculin Biotech Inc ,
Nasdaq ,
Twitter ,
British Journal ,
Moleculin Biotech ,
After Induction Therapy ,
Wolfram Dempke ,
European Chief Medical Officer ,
John Paul Waymack ,
Senior Chief Medical Officer ,
Waldemar Priebe ,
Advisory Board ,
Partial Response ,
Fast Track Status ,
Orphan Drug Designation ,
Transcription Modulator ,
Securities Act ,
Securities Exchange Act ,
Private Securities Litigation Reform Act ,
Nc ,
Biotechnology ,
Health Care Amp Hospitals ,
Medical Pharmaceuticals ,
Clinical Trials Amp Medical Discoveries ,
comparemela.com © 2020. All Rights Reserved.